Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition
- Conditions
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Mary Feng, MD
- Target Recruit Count
- 21
- Registration Number
- NCT04430452
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT04287894
- Locations
- 🇳🇱
Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- A.J.M. van den Eertwegh
- Target Recruit Count
- 13
- Registration Number
- NCT04274816
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 50
- Registration Number
- NCT04238637
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
🇩🇪Clinic Essen Center, Essen, Germany
🇩🇪University Hospital Essen, Essen, Germany
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
- Conditions
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 56
- Registration Number
- NCT04159974
- Locations
- 🇩🇪
Klinikum der Universität München, München, Germany
🇩🇪University of Cologne, Cologne, Germany
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Baki Topal
- Target Recruit Count
- 12
- Registration Number
- NCT04156087
- Locations
- 🇧🇪
University Hospitals KU Leuven, Leuven, Vlaams-Brabant, Belgium
Microbiome Immunotherapy Toxicity and Response Evaluation
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- CCTU- Cancer Theme
- Target Recruit Count
- 1800
- Registration Number
- NCT04107168
- Locations
- 🇬🇧
University Hospitals Dorest NHS Foundation Trust, Bournemouth, United Kingdom
🇬🇧Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
🇬🇧Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Daniel George, MD
- Registration Number
- NCT04073160
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
- Conditions
- Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Ovarian Serous AdenocarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaMalignant Ovarian Endometrioid TumorPlatinum-Sensitive Ovarian CarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPlatinum-Sensitive Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT04034927
- Locations
- 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.
- Conditions
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 100
- Registration Number
- NCT03994393
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺St Vincent's Hospital (Melbourne), Melbourne, Victoria, Australia
🇨🇳Taiwan Dalin Tzu Chi Hospital, Chiayi City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.